<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787967</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-01535BB1-01</org_study_id>
    <secondary_id>2015-005152-10</secondary_id>
    <nct_id>NCT02787967</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old</brief_title>
  <official_title>A Single-dose, Open-label, Randomized, 2-way Cross-over Study of CHF 1535 35/4 NEXThaler® (Fixed Combination of Beclometasone Dipropionate (BDP) 35 μg Plus Formoterol Fumarate (FF) 4 μg Versus the Free Combination of Licensed BDP DPI (Dry Powder Inhaler) and FF DPI in Asthmatic Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted in asthmatic children aged 5 to 11 years and is based on a
      single-dose, open-label, randomized, 2-way cross-over design where a Dry Powder Inhaler (DPI)
      fixed combination of beclometasone dipropionate (BDP) 35 μg plus formoterol fumarate (FF) 4
      μg is compared with the free combination of licensed BDP DPI and FF DPI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pharmacokinetic comparison of NEXThaler 35/4 μg versus the free combination of
      Beclomethasone DPI and Formoterol DPI in children (5 to 11 years old) of a formulation
      already approved in adults.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Area Under Curve (AUC0-t) for B17MP, active metabolite of BDP</measure>
    <time_frame>predose, 15,30min, 1,2,4,6,8 hours post dose</time_frame>
    <description>B17MP: Profile of Pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>B17MP Cmax</measure>
    <time_frame>predose, 15min,30min,1,2,4,6,8 hours post dose</time_frame>
    <description>17MP: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP Area Under Curve (AUC)</measure>
    <time_frame>predose, 15min,30min,1,2,4,6,8 hours post dose</time_frame>
    <description>BDP: profile of Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formoterol Area Under Curve (AUC), Cmax, Tmax, T1/2 [</measure>
    <time_frame>predose, 15min, 30 min, 1,2,4,6,8 hours postdose</time_frame>
    <description>Formoterol: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formoterol Cmax</measure>
    <time_frame>predose, 15min, 30 min, 1,2,4,6,8 hours postdose</time_frame>
    <description>Formoterol: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formoterol Tmax</measure>
    <time_frame>predose, 15min, 30 min, 1,2,4,6,8 hours postdose</time_frame>
    <description>Formoterol: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formoterol T1/2</measure>
    <time_frame>predose, 15min, 30 min, 1,2,4,6,8 hours postdose</time_frame>
    <description>Formoterol: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma potassium Area Under Curve (AUC)</measure>
    <time_frame>predose, 15min, 30min, 1, 2, 4, 6, 8 hours postdose</time_frame>
    <description>plasma potassium to evaluate drug systemic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma potassium Cmin</measure>
    <time_frame>predose, 15min, 30min, 1, 2, 4, 6, 8 hours postdose</time_frame>
    <description>plasma potassium to evaluate drug systemic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma potassium Tmin</measure>
    <time_frame>predose, 15min, 30min, 1, 2, 4, 6, 8 hours postdose</time_frame>
    <description>plasma potassium to evaluate drug systemic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Cortisol: Amount excreted in 0-8hours (Ae),8h cortisol urinary excretion normalized for 8h creatinine excretion (Ae/Aecreat).</measure>
    <time_frame>from predose up to 8 hours postdose</time_frame>
    <description>Urinary cortisol to evaluate drug systemic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B17MP Tmax</measure>
    <time_frame>predose, 15min,30min,1,2,4,6,8 hours post dose</time_frame>
    <description>BDP: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B17MP T1/2</measure>
    <time_frame>predose, 15min,30min,1,2,4,6,8 hours post dose</time_frame>
    <description>BDP: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP Cmax</measure>
    <time_frame>predose, 15min,30min,1,2,4,6,8 hours post dose</time_frame>
    <description>BDP: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP Tmax</measure>
    <time_frame>predose, 15min,30min,1,2,4,6,8 hours post dose</time_frame>
    <description>BDP: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP T1/2</measure>
    <time_frame>predose, 15min,30min,1,2,4,6,8 hours post dose</time_frame>
    <description>BDP: profile of pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>NEXThaler® 35/4µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1535 35/4µg NEXThaler® Dry Powder Inhaler, 4 inhalations. Total Dose: BDP 200µg FF 16µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: free comb. beclomethasone DPI and formoterol DPI 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 35/4µg NEXThaler®</intervention_name>
    <description>4 (four) inhalations (total dose: BDP/FF 140/16 µg)</description>
    <arm_group_label>NEXThaler® 35/4µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>free comb. beclomethasone DPI and formoterol DPI</intervention_name>
    <description>2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg</description>
    <arm_group_label>Reference treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/female children with asthma stable enough, according to paediatrician opinion, to
             allow a wash out period from steroids of 3 days before study treatments.

          -  Male/female children with asthma on regular treatment with ICS or using short-acting
             inhaled 2-agonist as reliever to control asthma symptoms.

          -  Age ≥ 5 &lt; 12 years (8 to 10 children in the age range 5-8 years old).

          -  Children with a forced expiratory volume in one second (FEV1)&gt;70% of predicted values
             (% pred) after withholding 2-agonists treatment for a minimum of 4 h prior to
             screening and to each study treatment.

          -  A cooperative attitude and ability to be trained about the proper use of DPI, ability
             to use correctly the medical devices and compliant to study procedures

        Exclusion Criteria:

          -  Past or present diagnosis of cardiovascular, renal or liver disease.

          -  Known hypersensitivity to the active treatmen

          -  Exacerbation of asthma symptoms within 4 weeks prior to screening.

          -  Inability to perform the required breathing technique and blood sampling.

          -  Hospitalization due to exacerbation of asthma within 1 month prior to screening (Visit
             1).

          -  Lower respiratory tract infection within 1 month prior to screening (Visit 1).

          -  Disease (other than asthma) which might influence the outcome of the study.

          -  Obesity, i.e. &gt; 97% weight percentile by local standards
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Bisgaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen Studies on Asthma in Childhood</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BørneAstmaKlinikken, Hans Knudsens Plads 1A,</name>
      <address>
        <city>Copenaghen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005152-10/results</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

